VVARDIS Secures $50 Million Funding to Expand Curodont™ Rollout

vVARDIS, a dental company based in Switzerland, has successfully closed a $50 million funding round with healthcare investment firm OrbiMed. This new investment builds on an initial $35 million, bringing total financing to $85 million. These funds aim to refinance existing facilities and accelerate the global expansion of Curodont™, a drill-free treatment for early tooth decay.

Since January 2024, vVARDIS has treated over one million teeth in the U.S., with nearly 10% of dental practices adopting the product. This reflects a wider market trend favouring non-invasive procedures, as emphasized by vVARDIS founders Drs. Haley and Goly Abivardi. The company collaborates with OrbiMed to address the global tooth decay epidemic, leveraging AI technology and innovative dental solutions to meet market needs.